<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405587</url>
  </required_header>
  <id_info>
    <org_study_id>PLX06-02</org_study_id>
    <nct_id>NCT00405587</nct_id>
  </id_info>
  <brief_title>Safety Study of PLX4032 in Patients With Solid Tumors</brief_title>
  <official_title>A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX4032 in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexxikon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Plexxikon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this FIH study is to assess the safety and pharmacokinetics of
      PLX4032 in patients with solid tumors. The secondary objective is to assess the
      pharmacodynamic activity in paired biopsy specimens obtained from patients with malignant
      melanoma who have the V600E BRAF oncogenic mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Activating mutations of the BRAF gene have been observed in a variety of cancers, including
      55-68% of malignant melanomas. In general, oncogenic mutations of BRAF correlate with a poor
      outcome. PLX4032 is a compound that selectively inhibits oncogenic B-Raf kinase.

      Two extension cohorts of patients with confirmed V600E mutations will be recruited,
      consisting of advanced melanoma and metastatic colorectal carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: subject incidence of adverse events, first-cycle DLTs and clinically significant changes in vital signs, ECGs and clinical laboratory tests</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity in tumor biopsy tissue as assess by paired biopsy (Day 15 vs. Baseline) quantitation of pERK and Ki67</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>PLX4032</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, sequential dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX4032</intervention_name>
    <description>Oral capsules administered BID</description>
    <arm_group_label>PLX4032</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Solid tumors confirmed histologically whose tumors are refractory to standard
             therapy, or for whom standard or curative therapy does not exist

          -  Patients from whom paired melanoma biopsies are planned must have a V600E+ BRAF
             mutation confirmed prior to the administration of PLX4032

          -  Previous chemotherapy, immunotherapy, or radiation therapy must have been completed
             at least 2 weeks prior to starting PLX4032 therapy, and all associated toxicity must
             be resolved prior to administration of PLX4032

          -  Patients in the Extension cohorts (melanoma or adenocarcinoma of the colon or rectum)
             must have both a V600E+ BRAF mutation and measurable disease (by RECIST V 1.0
             criteria) prior to the administration of PLX4032. All patients enrolled must provide
             archival or fresh melanoma tumor biopsy for confirmation of V600E+ BRAF mutation
             status by TaqMan assay

          -  ECOG performance status 0 or 1

          -  Life expectancy â‰¥ 3 months

          -  Adequate hematologic, hepatic, and renal function

        Exclusion Criteria:

          -  Brain metastases that are progressing or have been documented to be stable for less
             than 3 months, or for which systemic corticosteroids are required

          -  Investigational drug use within 28 days of the first dose of PLX4032

          -  Uncontrolled intercurrent illness

          -  Refractory nausea and vomiting, malabsorption, or significant bowel resection that
             would preclude adequate absorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Hsu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Plexxikon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.</citation>
    <PMID>20818844</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 19, 2015</lastchanged_date>
  <firstreceived_date>November 28, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
